Bristol-Myers Squibb (NYSE:BMY) reported positive top-line Phase 2 results for Reblozyl in alpha-thalassemia related anemia, ...
Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent expiries for revenue leaders Opdivo and Eliquis, says CEO ...
The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...
In late February 2026, Bristol Myers Squibb and partner SystImmune reported that antibody-drug conjugate izalontamab brengitecan (iza-bren) achieved statistically significant, clinically meaningful ...
Iberdomide shows deep and sustained responses in newly diagnosed multiple myeloma First-in-class lymphoma CELMoD™ agent, golcadomide, delivers durable responses in combinations across aggressive and ...
Bristol Myers Squibb is part of the biopharmaceutical sector, a segment defined by research driven drug development, global ...
Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Barclays began coverage of Bristol-Myers Squibb Company (NYSE:BMY) ...
Bristol Myers Squibb Company (NYSE:BMY) is one of the most undervalued large cap stocks to invest in now. On January 28, Piper Sandler raised its price target for Bristol Myers to $66 from $62, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results